Article Sidebar

Submitted
Feb 13, 2026
Accepted
Apr 20, 2026
Published
Apr 24, 2026
Download
pdf
Statistic
Read Counter : 12 Download : 8

Downloads

Download data is not yet available.

Main Article Content

Abstract

Jakarta, a densely populated megacity with high hybrid immunity, presents a unique epidemiological landscape for COVID-19. Understanding the clinical and hematological markers in this context is vital for improving clinical management. This study aims to analyze the clinical and hematological profiles of COVID-19 patients in Jakarta to identify markers associated with disease severity. This cross-sectional study analyzed secondary data from 100 confirmed COVID-19 patients (26 mild, 54 moderate, 20 severe) at two Jakarta hospitals. ANOVA and Kruskal-Wallis tests were employed to compare variables across severity groups, while categorical variables were analyzed using Chi-square tests. Significant associations with increasing severity were found for higher HR and RR. Among hematological parameters, basophil levels decreased significantly with higher severity. Although not statistically significant, trends of decreasing lymphocytes and platelets, alongside increasing blood glucose and neutrophils, were observed. Diabetes was the most prevalent comorbidity in severe cases. In conclusion, HR, RR, and basophils roles as significant markers of COVID-19 severity in our population. Trends in lymphocyte, thrombocyte, blood glucose, and diabetes prevalence, align with known patterns of severe disease with insignificant statistically, due to sample size limitations.

Keywords

clinical markers comorbid COVID-19 severity hematology

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
1.
Listiyaningsih E, Sari SDP, Martalena D, Sukarya W. The Spectrum of Severity: Clinical and Hematological Markers in Jakarta’s COVID-19 Patients. EKSAKTA [Internet]. 2026 Apr. 24 [cited 2026 Apr. 29];27(02):182-90. Available from: https://eksakta.ppj.unp.ac.id/index.php/eksakta/article/view/660

References

  1. [1] Branda, F., Ciccozzi, M., & Scarpa, F. (2025). Genome-based analyses of SARS-CoV-2 NB. 1.8. 1 variant reveals its low potential. Infectious Diseases, 57(8), 805-808.
  2. [2] Branda, F., Ciccozzi, M., & Scarpa, F. (2025). SARS-CoV-2 XFG: a genomic insight into the new recombinant. Infectious Diseases, 57(10), 1017-1020.
  3. [3] World Health Organization (WHO). (2025). WHO TAG-VE Risk Evaluation for SARS-CoV-2 Variant Under Monitoring : NB.1.8.1. 2025(April), 4–9.
  4. [4] World Health Organization (WHO). (2021). Living guidance for clinical management of COVID-19 (Issue November).
  5. [5] Patange, A. P., Desai, J. V., Pujari, B., Marwah, A., Dey, A., & Patange, A. (2024). Dynamic Assessment of Hematological Parameters as Predictive Biomarkers for Disease Severity and Prognosis in COVID-19 Patients: A Longitudinal Study. Cureus, 16(7).
  6. [6] Suryawanshi, S. Y., Priya, S., Sinha, S. S., Soni, S., Haidry, N., Verma, S., & Singh, S. (2021). Dynamic profile and clinical implications of hematological and immunological parameters in COVID-19 patients. A retrospective study. Journal of Family Medicine and Primary Care, 10(7), 2518-2523.
  7. [7] Henry, B. M., De Oliveira, M. H. S., Benoit, S., Plebani, M., & Lippi, G. (2020). Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM), 58(7), 1021-1028.
  8. [8] Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A., & Ozben, T. (2020). Biomarkers associated with COVID-19 disease progression. Critical reviews in clinical laboratory sciences, 57(6), 389-399.
  9. [9] Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis, 18(4), 844-847.
  10. [10] Barbé-Tuana, F., Funchal, G., Schmitz, C. R. R., Maurmann, R. M., & Bauer, M. E. (2020, October). The interplay between immunosenescence and age-related diseases. In Seminars in immunopathology (Vol. 42, No. 5, pp. 545-557). Berlin/Heidelberg: Springer Berlin Heidelberg.
  11. [11] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497-506.
  12. [12] Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., ... & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 395(10229), 1054-1062.
  13. [13] Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., ... & Tang, W. (2020). Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of infection, 81(2), e16-e25.
  14. [14] Ariawan, I., Jusril, H., N Farid, M., Riono, P., Wahyuningsih, W., Widyastuti, W., ... & Pronyk, P. M. (2022). SARS-CoV-2 Antibody Seroprevalence in Jakarta, Indonesia. Kesmas, 17(3), 169-174.
  15. [15] Asysyifa, N., Sari, S. D. P., & Martalena, D. (2023). Association between blood glucose levels at admission and severity of COVID-19 patients. Berkala Ilmu Kedokteran, 55(4), 298-305.
  16. [16] Shi, Z., Zhang, H., Zhang, R., & Zhu, L. (2021). Stochastic dynamics of the COVID-19 case-fatality ratios in indonesia, malaysia, and the philippines: economic implications for the post-COVID-19 era. Frontiers in Public Health, 9, 755047.
  17. [17] Kusumaratna, R. (2022). Interpreting Epidemiological Data of Coronavirus Disease 2019 in Indonesia and Its Implication for Travel Advice: a lesson learned.
  18. [18] Farheen, S., Agrawal, S., Zubair, S., Agrawal, A., Jamal, F., Altaf, I., ... & Owais, M. (2021). Patho-physiology of aging and immune-senescence: possible correlates with comorbidity and mortality in middle-aged and old COVID-19 patients. Frontiers in Aging, 2, 748591.
  19. [19] Liu, Z., Liang, Q., Ren, Y., Guo, C., Ge, X., Wang, L., ... & Han, X. (2023). Immunosenescence: molecular mechanisms and diseases. Signal transduction and targeted therapy, 8(1), 200.
  20. [20] Bhopal, S. S., & Bhopal, R. (2020). Sex differential in COVID-19 mortality varies markedly by age. Lancet (London, England), 396(10250), 532.
  21. [21] Li, A. J., & Li, X. (2021). Sex-dependent immune response and lethality of COVID-19. Stem Cell Research, 50, 102116.
  22. [22] Chen, J., Wu, C., Wang, X., Yu, J., & Sun, Z. (2020). The impact of COVID-19 on blood glucose: a systematic review and meta-analysis. Frontiers in endocrinology, 11, 574541.
  23. [23] Zhu, L., She, Z. G., Cheng, X., Qin, J. J., Zhang, X. J., Cai, J., ... & Li, H. (2020). Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell metabolism, 31(6), 1068-1077.
  24. [24] Coppelli, A., Giannarelli, R., Aragona, M., Penno, G., Falcone, M., Tiseo, G., ... & Del Prato, S. (2020). Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. Diabetes care, 43(10), 2345-2348.
  25. [25] Kulkarni, S., Fernandes, J., Selvam, S., & Idiculla, J. (2022). A Study of the Profile and the Impact of Diabetes, Steroid and Stress Hyperglycaemia on COVID-19 Outcomes. Indian Journal of Endocrinology and Metabolism, 26(6), 551-557.
  26. [26] Nhau, P. T., Gamede, M., & Sibiya, N. (2024). COVID-19-induced diabetes mellitus: Comprehensive cellular and molecular mechanistic insights. Pathophysiology, 31(2), 197-209.
  27. [27] Terpos, E., Ntanasis‐Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T. N., Politou, M., ... & Dimopoulos, M. A. (2020). Hematological findings and complications of COVID‐19. American journal of hematology, 95(7), 834-847.
  28. [28] Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., ... & Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. jama, 323(11), 1061-1069.
  29. [29] Wingert, A., Pillay, J., Gates, M., Guitard, S., Rahman, S., Beck, A., ... & Hartling, L. (2021). Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada. BMJ open, 11(5), e044684.
  30. [30] Fatmawati, F., & Mulyanti, S. (2023). Risk factors associated with the severity of COVID-19. The Malaysian journal of medical sciences: MJMS, 30(3), 84.